Whilst its role in CML is not well characterized, BCL6 is expressed at low levels in TKI-naïve CML cells, however, its levels are significantly upregulated following TKI treatment in CML cell lines and primary CD34+ cells (Hurtz et al., 2011; Madapura et al., 2017). The gene discussed is BCL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.